SPONSOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Total Trials

Recruiting

Phases

Phase 2, EARLY_Phase 1, Phase 1, Phase 2, Phase 3, Phase 1

Conditions studied: Head and Neck Cancer Locally Advanced Esophageal Squamous Cell Carcinoma Sintilimab Radiotherapy Concurrent Chemoradiotherapy Immunonutrition Esophageal Cancer Nimotuzumab Chemoradiotherapy Chemotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is a clinical research sponsor with 28 registered studies on ClinicalTrials.gov, of which 28 are actively recruiting participants. Research covers conditions including Head and Neck Cancer, Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy.

The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

How many clinical trials has Cancer Institute and Hospital, Chinese Academy of Medical Sciences sponsored?

ClinicalMetric currently tracks 28 clinical trials sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, of which 28 are actively recruiting participants. These trials cover conditions including Head and Neck Cancer, Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Cancer Institute and Hospital, Chinese Academy of Medical Sciences research focus on?

Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trials span Head and Neck Cancer, Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trial?

To participate in a Cancer Institute and Hospital, Chinese Academy of Medical Sciences trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials with current recruitment status updated daily.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Frequently Asked Questions — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Clinical Trials by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors

Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer

Neoadjuvant Treatment Modalities in Esophageal Cancer

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era

NV-001 in the Treatment of Advanced Solid Tumors

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

Super-Hypofractionated Partial Breast Irradiation

YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)